Inactive Instrument

Regenicin Inc Stock OTC Bulletin Board

US75887Q1022

Biotechnology & Medical Research

End-of-day quote OTC Bulletin Board
- ^USD	-

04-22	Made Scientific, Inc. And Regenicin, Inc. Announce Manufacturing Relationship To Advance NovaDerm Toward FDA Product Approval	CI
23-05-15	Regenicin, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	CI

Regenicin, Inc. is a biotechnology company specializes in the development of regenerative cell therapies to restore the health of damaged tissues and organs. The Company is focused on developing and commercializing a lifesaving technology through the introduction of tissue-engineered skin substitutes to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds and a range of plastic surgery procedures. Its product, NovaDerm, is a multi-layered tissue-engineered skin prepared by utilizing autologous skin cells. NovaDerm is a graftable cultured epithelium skin substitute containing both epidermal and dermal components. Its second product is TempaDerm. TempaDerm uses cells obtained from human donors to develop banks of cryo-preserved (frozen) cells and cultured skin substitutes to provide a continuous supply of non-allogenic skin substitutes to treat much smaller wound areas on patients, such as ulcers.

Employees

Sector

Biotechnology & Medical Research

More about the company

All transcripts on over 9000 companies, on the day they post their earnings!

Unlock them now!

Market Cap	76.74K 66.07K 62.04K 56.63K 106K 7.3M 107K 735K 286K 3.7M 288K 282K 12.26M	P/E 2021	-2x	P/E 2022	-0.71x
Enterprise Value	704K 606K 569K 520K 976K 67M 983K 6.75M 2.62M 33.98M 2.64M 2.59M 112M	EV / Sales 2021	-	EV / Sales 2022	-
Free-Float	96.65%	Yield 2021 *	-	Yield 2022	-

04-22	Made Scientific, Inc. And Regenicin, Inc. Announce Manufacturing Relationship To Advance NovaDerm Toward FDA Product Approval	CI
23-05-15	Regenicin, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	CI
23-02-13	Regenicin, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2022	CI
23-01-13	Regenicin, Inc. Reports Earnings Results for the Full Year Ended September 30, 2022	CI
22-08-12	Regenicin, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2022	CI
22-05-23	Regenicin, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2022	CI
22-02-14	Regenicin, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2021	CI
22-01-13	Regenicin, Inc. Reports Earnings Results for the Full Year Ended September 30, 2021	CI
21-08-23	Regenicin, Inc. Reports Earnings Results for the Third Quarter Ended June 30, 2021	CI
21-05-17	Regenicin, Inc. Reports Earnings Results for the Second Quarter Ended March 31, 2021	CI
21-01-13	Regenicin, Inc. Reports Earnings Results for the Full Year Ended September 30, 2020	CI
20-08-19	Regenicin, Inc. Reports Earnings Results for the Third Quarter Ended June 30, 2020	CI
20-05-20	Regenicin, Inc. Reports Earnings Results for the Second Quarter Ended March 31, 2020	CI

24-12-23	Regenicin : Material Event Form 8 K	PU
24-11-06	Regenicin : Change in Certifying Accountants Form 8 K	PU
23-02-13	REGENICIN, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ
23-01-13	REGENICIN, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	AQ
22-08-12	REGENICIN, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ

Manager	Title	Age	Since
Randall McCoy CEO	Chief Executive Officer	76	2011-01-23
John Weber DFI	Director of Finance/CFO	76	2010-09-12
Scott Blow COO	Chief Operating Officer	-	2022-08-31

Director	Title	Age	Since
John Weber BRD	Director/Board Member	76	2010-09-12
Randall McCoy CHM	Chairman	76	2010-07-14

Regenicin Inc Stock OTC Bulletin Board

Stocks

US75887Q1022

Biotechnology & Medical Research

Valuation : Regenicin Inc

Latest news : Regenicin Inc

Press Releases : Regenicin Inc

Managers and Directors : Regenicin Inc

Bio Therapeutic Drugs

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WUXI APPTEC CO., LTD.	-1.66%	-4.96%	+49.84%	+88.43%	68.13B
ARGENX SE	+1.46%	+1.09%	+46.72%	+85.86%	63.6B
WUXI BIOLOGICS (CAYMAN) INC.	+1.31%	+1.81%	+37.52%	+12.07%	25.57B
INSMED INCORPORATED	-0.44%	-2.48%	-16.85%	+433.66%	26.6B
BIONTECH SE	-0.32%	-10.76%	+1.15%	-16.40%	25.52B
PHARMAESSENTIA CORPORATION	-9.71%	-0.36%	+245.87%	+377.68%	18.23B
GENMAB A/S	+0.54%	+1.75%	+31.00%	-18.60%	19.69B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.49%	-6.35%	+0.78%	+540.26%	15.16B
EXELIXIS, INC.	+1.37%	-2.56%	+48.66%	+143.05%	13.54B
Average	-1.00%	-2.71%	+49.41%	+182.89%	30.67B
Weighted average by Cap.	-0.63%	-2.34%	+45.90%	+143.31%

	2021	2022
Net sales	-	-
Net income	-877K -755K -709K -647K -1.22M -83.46M -1.22M -8.4M -3.27M -42.32M -3.29M -3.22M -140M	-639K -550K -517K -472K -886K -60.83M -893K -6.12M -2.38M -30.84M -2.4M -2.35M -102M
Net Debt	598K 515K 484K 442K 829K 56.93M 835K 5.73M 2.23M 28.87M 2.25M 2.2M 95.58M	627K 540K 507K 463K 870K 59.7M 876K 6.01M 2.34M 30.27M 2.36M 2.3M 100M